JNJ's pipeline remains a key growth driver, with new launches, late-stage data and approvals supporting momentum through the rest of 2026 and beyond.
Zacks
More News
J&J's New Growth Powerhouses: Immunology and Neuroscience
J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.
Zacks
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
Zacks
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +8.53% and -3.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of -10.24% and -2.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?
Zacks
Best Momentum Stocks to Buy for July 13th
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
Zacks
New Strong Buy Stocks for July 13th
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.